Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Oligodendroglioma 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 76Temozolomide 73Specimen Handling 49Radiotherapy 46Radiosurgery 34Cyclophosphamide 28Bevacizumab 26Radiation 25pembrolizumab 24Biopsy 23Nivolumab 21Carboplatin 16fludarabine 14X-Rays 13Ipilimumab 13Surgical Procedures, Operative 12Lomustine 12Irinotecan 12Vincristine 11Topotecan 11Cisplatin 11Blood Specimen Collection 11dinutuximab 10trametinib 9abemaciclib 9AZD 6244 9lutetium Lu 177 dotatate 8Immunoglobulin G 8Etoposide 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
vocimagene amiretrorepvec × CNS × 90 days × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

NCT06504381 2026-03-11

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

University of California, San Francisco

Phase 1/2 Recruiting
70 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡